data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Abcam PLC

(NASDAQ:ABCM)

Perks Buy Compare Brokers

$23.98

0.01[0.04%]

Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here

$23.98

0[0.00%]

After-Hours

Perks Buy Compare Brokers

Open23.980	Close23.970
Vol / Avg.8.518M / 6.084M	Mkt Cap5.519B
Day Range23.960 - 23.980	52 Wk Range12.480 - 25.320

0

Latest News for Abcam Stock (NASDAQ:ABCM)

Abcam Stock (NASDAQ: ABCM)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, November 17, 2023

Abcam Has Obtained All Clearances Required In Connection With Proposed Acquisition By Danaher For $24.00 Per Share In Cash
Benzinga Newsdesk - Nov 17, 2023, 7:08AM

Monday, November 06, 2023

Abcam Shareholders Approve Proposed Acquisition By Danaher
Benzinga Newsdesk - Nov 6, 2023, 4:01PM

Tuesday, October 31, 2023

RBC Capital Maintains Sector Perform on Abcam, Lowers Price Target to $24
Benzinga Newsdesk - Oct 31, 2023, 9:57AM

Monday, October 23, 2023

Jonathan Milner Welcomes Glass Lewis Report Insights, Urges Shareholders To Reject Abcam's Sale To Danaher
Benzinga Newsdesk - Oct 23, 2023, 2:57AM

Monday, October 16, 2023

Jonathan Milner Releases Presentation To Abcam Shareholders, Outlining Reasons To Reject Danaher's Bid And Strategic Vision For The Company
Benzinga Newsdesk - Oct 16, 2023, 10:34AM

Monday, October 09, 2023

RBC Capital Reiterates Sector Perform on Abcam, Maintains $25 Price Target
Benzinga Newsdesk - Oct 9, 2023, 9:34AM

Thursday, October 05, 2023

Abcam Files And Mails Scheme Circular Seeking Approval Of Acquisition Of Abcam By Danaher For $24.00 Per Share
Benzinga Newsdesk - Oct 5, 2023, 8:12AM

Thursday, September 28, 2023

Jonathan Milner, The Founder And One Of The Largest Investors In Abcam, Urges Shareholders To Reject The Danaher Acquisition In An Open Letter
Benzinga Newsdesk - Sep 28, 2023, 3:29AM

Wednesday, September 27, 2023

Danaher Bears The Brunt Of Macro Woes: Analyst Flags Lower Demand, Reduced Funding & Weakness In China
Nabaparna Bhattacharya - Sep 27, 2023, 3:37PM

Friday, September 15, 2023

Abcam Expresses Surprise At Dr. Milner's Actions, Believes His Opposition May Be An Attempt To Create Confusion Among Shareholders Before The Vote
Benzinga Newsdesk - Sep 15, 2023, 2:07AM

Thursday, September 14, 2023

Abcam Founder And One Of Its Largest Investors, Jonathan Milner, Announces His Decision To Vote Against The Proposed Acquisition Of Abcam By Danaher Corporation; Requests General Meeting To Replace Company's Board, CEO, CFO And Chairman
Benzinga Newsdesk - Sep 14, 2023, 8:13AM

Thursday, August 31, 2023

Abcam Says Due To The pending Acquisition, FY23 And FY24 Has Been Suspended.
Benzinga Newsdesk - Aug 31, 2023, 4:20PM
Abcam H1 Sales $221.47M Down From $240.75M YoY
Benzinga Newsdesk - Aug 31, 2023, 4:19PM

Wednesday, August 30, 2023

Benzinga's Top Ratings Upgrades, Downgrades For August 30, 2023
Benzinga Insights - Aug 30, 2023, 11:00AM
SVB Leerink Downgrades Abcam to Market Perform, Announces $24 Price Target
Benzinga Newsdesk - Aug 30, 2023, 4:33AM

Tuesday, August 29, 2023

Danaher's Strategic Abcam Deal Boosts Growth at a Reasonable Price: Analyst
Vandana Singh - Aug 29, 2023, 3:09PM
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Vandana Singh - Aug 29, 2023, 8:17AM

Monday, August 28, 2023

Health Care Company Danaher Announces Acquisition of Abcam
Benzinga Insights - Aug 28, 2023, 11:10AM
Danaher Acquires Abcam In $5.7B Deal; ABCM Is Sliding Below Deal Price - Here's Why
Akanksha Bakshi - Aug 28, 2023, 9:18AM
Danaher Agrees To Acquire Abcam Plc For $24.00 Per Share In Cash, Or Total Enterprise Value Of $5.7B, Including Assumed Indebtedness And Net Of Acquired Cash
Benzinga Newsdesk - Aug 28, 2023, 7:32AM

Friday, August 25, 2023

Check Out What Whales Are Doing With ABCM
Benzinga Insights - Aug 25, 2023, 3:30PM
Danaher The Lead To Acquire Abcam Prevailing Over Bid From Agilent Technologies
Benzinga Newsdesk - Aug 25, 2023, 1:54PM

Tuesday, August 22, 2023

Expert Ratings for Abcam
Benzinga Insights - Aug 22, 2023, 2:00PM
RBC Capital Reiterates Sector Perform on Abcam, Maintains $25 Price Target
Benzinga Newsdesk - Aug 22, 2023, 8:00AM

Wednesday, July 05, 2023

Abcam Says Total Revenue And Adjusted Operating Profit Are Trending In-line With First Half And Full Year 2023 Board Expectations
Benzinga Newsdesk - Jul 5, 2023, 4:50PM

Friday, June 30, 2023

Watching Abcam; Co Seeing Takeover Interest From Danaher, Agilent Technologies, Germany's Merck KGaA
Happy Mohamed - Jun 30, 2023, 12:26PM
Abcam shares are trading higher following a report suggesting the company has seen takeover interest.
Benzinga Newsdesk - Jun 30, 2023, 12:26PM

Tuesday, June 27, 2023

Abcam Provides FY24 Guidance & Confirms FY23 Outlook
Lekha Gupta - Jun 27, 2023, 6:14AM

Monday, June 26, 2023

Starboard Says 'We believe there is significant value in Abcam and are supportive of the Company running a full sale process to maximize value for all shareholders.'
Bill Haddad - Jun 26, 2023, 6:02PM
Abcam Sees FY24 Reported Revenue £475M-£525M
Bill Haddad - Jun 26, 2023, 4:11PM

Friday, June 23, 2023

Abcam shares are trading higher after the company announced an initiative to explore strategic alternatives including a potential sale.
Benzinga Newsdesk - Jun 23, 2023, 11:42AM
Why Abcam Shares Are Soaring Today
Akanksha Bakshi - Jun 23, 2023, 10:49AM
Abcam Plc Shares Resume Trade
Benzinga Newsdesk - Jun 23, 2023, 8:30AM
Abcam plc Shares To Resume Trade At 8:30 a.m. ET
Benzinga Newsdesk - Jun 23, 2023, 8:26AM
Abcam Plc Shares Halted On Code News Pending
Benzinga Newsdesk - Jun 23, 2023, 8:25AM
Abcam Has Decided To Initiate A Process To Explore Strategic Alternatives, Including A Potential Sale Of The Company. As Previously Disclosed, Abcam Has Received Strategic Inquiries From Multiple Parties Over The Past Few Weeks
Benzinga Newsdesk - Jun 23, 2023, 8:03AM

Wednesday, June 21, 2023

Jonathan Milner Issues Open Letter To Shareholders Of Abcam plc; Urges Shareholders To Vote Blue Proxy Card
Benzinga Newsdesk - Jun 21, 2023, 7:12AM

Tuesday, June 20, 2023

Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
Vandana Singh - Jun 20, 2023, 2:37PM
Abcam shares are trading lower after RBC downgraded the stock from Outperform to Sector Perform.
Benzinga Newsdesk - Jun 20, 2023, 2:31PM
Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023
Benzinga Insights - Jun 20, 2023, 11:02AM
RBC Capital Downgrades Abcam to Sector Perform, Lowers Price Target to $22
Benzinga Newsdesk - Jun 20, 2023, 5:01AM

Friday, June 16, 2023

Abcam shares are trading higher after the company disclosed it received strategic inquires from multiple parties over recent weeks. Also, B of A Securities upgraded the stock from Neutral to Buy and announced a $25 price target.
Benzinga Newsdesk - Jun 16, 2023, 2:47PM
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
Benzinga Insights - Jun 16, 2023, 11:01AM
B of A Securities Upgrades Abcam to Buy, Announces $25 Price Target
Benzinga Newsdesk - Jun 16, 2023, 7:11AM

Monday, June 12, 2023

Analyst Ratings for Abcam
Benzinga Insights - Jun 12, 2023, 3:00PM
Morgan Stanley Maintains Equal-Weight on Abcam, Maintains $19 Price Target
Benzinga Newsdesk - Jun 12, 2023, 9:21AM

Wednesday, May 17, 2023

Abcam Says Founder And Former Director Jonathan Milner Has Indicated Steps To Call An Extraordinary General Meeting To Elect Himself As Executive Chairman
Benzinga Newsdesk - May 17, 2023, 4:20PM

Thursday, May 04, 2023

Abcam Business Update FY23 Revenue Guidance Of ~£420M-£440M, Representing 15%-20% Constant Exchange Rate Revenue Growth; FY24 Revenue Goals Of £450M-£525M With Adjusted Operating Profit Margins Of Greater Than 30%
Happy Mohamed - May 4, 2023, 5:26PM

Friday, April 28, 2023

RBC Capital Maintains Outperform on Abcam, Raises Price Target to $23
Benzinga Newsdesk - Apr 28, 2023, 12:07PM

Friday, April 14, 2023

Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Apr 14, 2023, 1:02PM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved